Summit Therapeutics SMMT Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's preferred stock, shares authorized?
- Summit Therapeutics (SMMT) reported preferred stock, shares authorized of $20M in Q1 2026.
- How has Summit Therapeutics's preferred stock, shares authorized changed year-over-year?
- Summit Therapeutics's preferred stock, shares authorized decreased by 0.0% year-over-year, from $20M to $20M.
- What is the long-term trend for Summit Therapeutics's preferred stock, shares authorized?
- Over 4 years (2021 to 2025), Summit Therapeutics's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $20M to $20M.